The products are sold as:
Tetrasil
Genisil
Aviralex
OXi-MED
Imulux
Beta-mannan
Micronutrient
Qina
SlicPlus
The products falsely claim to prevent or treat a variety of sexually transmitted diseases (STDs), including:
herpes
chlamydia
human papillomavirus (HPV)
cervical dysplasia
HIV/AIDS
Some of these products falsely claim to have "FDA Approval" and some claim to be "more effective" than conventional medicine. Examples of claims that these products make include
"Treatment Kills all Herpes Viruses WITHOUT having to use conventional drugs or medications"
"Greatest STD Protection Without Condoms"
"The active ingredient in our product is FDA certified to destroy 99.9992 percent of all pathogenic organisms [i.e.] Chlamydia"
Why Consumers Should be Concerned
"STDs are very serious diseases and these products give consumers a false sense of security that they are protected from STDs," says Janet Woodcock, M.D., Director of FDA's Center for Drug Evaluation and Research.
What Consumers Should Do
Stop using these products immediately.
Contact your health care professional if you have used any of these products and experienced any bad reactions.
For More Information :
http://www.fda.gov/consumer/updates/STDs031208.html
Beyond Organic Healthy Food



Tuesday, March 11, 2008
ReplyDeleteFDA DEAD wrong about Tetrasil
via email
Re: FDA Warns Companies Importing and Marketing Drugs Over the Internet that Fraudulently Claim to Prevent and Treat STDs
Dear Ms. Chappelle:
The FDA can not simply have it both ways. The 1997 government patent on tetrasil speaks for itself. The FDA is merely standing in the way of restoring the health of millions and millions of people, mostly of color. To date, the FDA has never addressed the U.S. Special (Cancer) Virus program (1962 – 1978).
To date, the FDA has never addressed the visna sheep sequences in the blood of people with HIV/AIDS. See, PROC NAS Vol. 83, pp. 4007 – 11, June 1986. See also, PROC NAS Vol. 92, pp. 3283 – 3287, April 11, 1995.
The current 2008 “Understanding HIV and AIDS” poster is identical to the virus created in the Special Virus program. See, Nature New Biology, Vol. 232, pp. 140 – 2, 1971.
The U.S. patent below deserves “immediate scrutiny” from the FDA, not tomorrow, today.
Boyd Ed Graves, J.D.
www.boydgraves.com
619-849-9364